<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837173</url>
  </required_header>
  <id_info>
    <org_study_id>ECLNI-MC2013</org_study_id>
    <nct_id>NCT01837173</nct_id>
  </id_info>
  <brief_title>Multicentric Retrospective Review of Extracapsular Lymph Node Involvement After Esophagectomy</brief_title>
  <acronym>ECLNI-MC</acronym>
  <official_title>Can Extracapsular Lymph Node Involvement be a Tool to Fine-tune UICC TNM 7th Edition for Esophageal Carcinoma?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that lymph node metastasis is one of the most important prognostic factors&#xD;
      in oesophageal carcinoma.&#xD;
&#xD;
      The investigators want to determine the influence of lymph node characteristics, being either&#xD;
      intracapsular or extracapsular, on overall survival after esophagectomy for esophageal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The classification of carcinoma of the esophagus has undergone a major modification between&#xD;
      the UICC sixth (TNM-6) and TNM-7 edition. Regional lymph nodes (N) are now subdivided by the&#xD;
      number of involved lymph nodes (pN0, 0; pN1, 1-2; pN2, 3-6; pN3 &gt; 6), and distant metastasis&#xD;
      (M) has been simplified to M1 rather than subdivided by location [1].&#xD;
&#xD;
      Nevertheless, TNM-7 doesn't take into consideration the morphologic characteristics of the&#xD;
      metastatic lymph node itself. Since our first publications showing a negative relationship&#xD;
      between presence of extracapsular lymph node involvement (EC-LNI) and survival [2], little&#xD;
      has been published about the prognostic impact of this specific characteristic .&#xD;
&#xD;
      In our latest publication &quot;Can extracapsular lymph node involvement be a tool to fine-tune&#xD;
      pN1 for adenocarcinoma in UICC TNM 7th Edition?&quot; [3], the investigators found a significant&#xD;
      survival benefit for adenocarcinoma without extracapsular lymph node involvement in pN1 (=&#xD;
      1-2 positive lymph nodes) as compared to N2-N3 disease, treated by primary surgery. Moreover,&#xD;
      pN1 patients with extracapsular lymph node involvement (EC-LNI) showed a survival that was&#xD;
      comparable to patients with more than 2 positive lymph nodes (i.e. stage IIIB). These&#xD;
      findings may have important consequences for future TNM adaptations.&#xD;
&#xD;
      The aim of this study is to validate our results on a larger, multicentric cohort, and if&#xD;
      possible make recommendations and possible fine-tuning for a future TNM adaptation, including&#xD;
      the characteristics of the metastatic lymph node itself, being intra- or extracapsular.&#xD;
&#xD;
      Furthermore the investigators want to examine if these effects are valid in pre-treated&#xD;
      patients, i.e. surgery after neoadjuvant chemo(radiation) therapy. Although these patients&#xD;
      are not incorporated in the current TNM classification, future adaptations to the TNM&#xD;
      classification system will also examine the effects of neoadjuvant therapy (cfr.&#xD;
      Rice/Blackstone WECC -Worldwide Esophageal Cancer Collaboration).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival by LN-status (being ECLNI or ICLNI)</measure>
    <time_frame>5 yrs from surgery</time_frame>
    <description>according UICC TNM7 pN (pN1-2-3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer-specific survival by LN-status (being ECLNI or ICLNI)</measure>
    <time_frame>5 yrs from surgery</time_frame>
    <description>according UICC TNM7 pN (pN1-2-3)- censoring non-esophageal cancer related deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival for intra- and extracapsular lymph node involvement</measure>
    <time_frame>5 yrs from surgery</time_frame>
    <description>Differentiation of intra- and extracapsular lymph node involvement after neoadjuvant chemo(radio)therapy followed by surgery versus primary surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cancer specific survival for intra- and extracapsular lymph node involvement</measure>
    <time_frame>5 yrs from surgery</time_frame>
    <description>Differentiation of intra- and extracapsular lymph node involvement by histology, being Adenocarcinoma or Squamous cell carcinoma.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Extracapsular LNI</arm_group_label>
    <description>Patients with positive lymph nodes that show extracapsular lymph node involvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracapsular LNI</arm_group_label>
    <description>Patients with positive lymph nodes that show NO extracapsular lymph node involvement</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Multicentric cohort study, patient chart analysis Since several high volume European&#xD;
        institutions have published their results on patients with extracapsular lymph node&#xD;
        involvement, we plan a pooling of their 'raw' data regarding type of treatment, histology,&#xD;
        extracapsular LNI and (disease-free) survival.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adequate lymph node sampling is of paramount importance. (pT1 - min. 10 LN; &gt;pT2 min.&#xD;
             20 LN resected). At least the following lymph node stations should be examined:&#xD;
             perioesophageal distal 1/3 and perigastric LN, left gastric artery, splenic artery,&#xD;
             common hepatic artery, subcarinal lymph nodes. Sugical technique (transthoracic,&#xD;
             transhiatal or minimal invasive) is less important if the criterium of adequate lymph&#xD;
             node sampling is fulfilled but should be mentioned.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unforeseen organ metastasis&#xD;
&#xD;
          -  subcardia tumors&#xD;
&#xD;
          -  histology other than adenocarcinoma or squamous cell carcinoma&#xD;
&#xD;
          -  Postoperative (inhospital or 30-day) mortality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Leuven, Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gasthuisberg</investigator_affiliation>
    <investigator_full_name>Johnny Moons</investigator_full_name>
    <investigator_title>RN, MSc, Datamanager</investigator_title>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>Esophagectomy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

